Iron Triangle Partners’s 10x Genomics TXG Stock Holding History

Iron Triangle Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,000,000	Closed	-$8.73M	–	37
2025 Q1	$8.73M	Buy	+1,000,000	New	+$12.6M	1.38%	27
2024 Q1	–	Sell	-479,374	Closed	-$26.8M	–	39
2023 Q4	$26.8M	Sell	479,374 -187,571	-28%	-$8.16M	3.47%	15
2023 Q3	$27.5M	Buy	666,945 +286,945	+76%	+$14.9M	4.02%	14
2023 Q2	$21.2M	Buy	380,000 +30,000	+9%	+$1.62M	2.84%	16
2023 Q1	$19.5M	Buy	+350,000	New	+$16.3M	2.82%	18

Other funds holding TXG

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Iron Triangle Partners's TXG Position: Q2 2025 in Review

Iron Triangle Partners sold out of 10x Genomics (TXG) in Q2 2025, closing a stake of 1,000,000 shares — an estimated $8.73M sold.

Iron Triangle Partners first reported a position in TXG in Q1 2023 and held it in 5 quarters. The position peaked at $27.5M in Q3 2023. 297 funds tracked by Wall St. Rank hold TXG as of Q2 2025.

Iron Triangle Partners reported no remaining 10x Genomics position as of Q2 2025 after selling out during the quarter.
Iron Triangle Partners sold 1,000,000 10x Genomics shares in Q2 2025, an estimated $8.73M.
Iron Triangle Partners first reported a position in 10x Genomics in Q1 2023 and held it in 5 quarters.
Iron Triangle Partners's 10x Genomics position peaked at $27.5M in Q3 2023.
297 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2025.

Based on Iron Triangle Partners's 13F filing for Q2 2025, filed 14 Aug 2025.